mirvetuximab soravtansine   Click here for help

GtoPdb Ligand ID: 12250

Synonyms: Elahere® | IMGN-853 | IMGN853 | M9346A-sulfo-SPDB-DM4 | mirvetuximab soravtansine-gynx
Approved drug
mirvetuximab soravtansine is an approved drug (FDA (2022))
Compound class: Antibody
Comment: Mirvetuximab soravtansine (IMGN853) is an antibody-drug conjugate (ADC) that delivers the cytotoxic maytansinoid DM4 (a microtubule toxin) to cancer cells that express the folate receptor α (FOLR1; P15328) [2]. FOLR1 is an active oncology drug target [10]. Mirvetuximab soravtansine has proven particularly effective against FLOR1 +ve, advanced ovarian tumours [1,5,9].
The chemical structure of DM4 and its sulfo-SPDB linker is represented in PubChem CID 131704480.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
References
1. Ab O, Whiteman KR, Bartle LM, Sun X, Singh R, Tavares D, LaBelle A, Payne G, Lutz RJ, Pinkas J et al.. (2015)
IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors.
Mol Cancer Ther, 14 (7): 1605-13. [PMID:25904506]
2. Altwerger G, Bonazzoli E, Bellone S, Egawa-Takata T, Menderes G, Pettinella F, Bianchi A, Riccio F, Feinberg J, Zammataro L et al.. (2018)
In Vitro and In Vivo Activity of IMGN853, an Antibody-Drug Conjugate Targeting Folate Receptor Alpha Linked to DM4, in Biologically Aggressive Endometrial Cancers.
Mol Cancer Ther, 17 (5): 1003-1011. [PMID:29440294]
3. Corbelli E, Miserocchi E, Marchese A, Giuffrè C, Berchicci L, Sacconi R, Bandello F, Modorati GM. (2019)
Ocular Toxicity of Mirvetuximab.
Cornea, 38 (2): 229-232. [PMID:30379722]
4. Dilawari A, Shah M, Ison G, Gittleman H, Fiero MH, Shah A, Hamed SS, Qiu J, Yu J, Manheng W et al.. (2023)
FDA Approval Summary: Mirvetuximab Soravtansine-Gynx for FRα-Positive, Platinum-Resistant Ovarian Cancer.
Clin Cancer Res, 29 (19): 3835-3840. [PMID:37212825]
5. Fowler M. (2020)
Mirvetuximab Soravtansine Combination Yields Encouraging Response Rates in Ovarian Cancer.
Oncology (Williston Park), 34 (7): 250. [PMID:32674207]
6. Heo YA. (2023)
Mirvetuximab Soravtansine: First Approval.
Drugs, 83 (3): 265-273. [PMID:36656533]
7. Moore KN, Angelergues A, Konecny GE, García Y, Banerjee S, Lorusso D, Lee JY, Moroney JW, Colombo N, Roszak A et al.. (2023)
Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer.
N Engl J Med, 389 (23): 2162-2174. [PMID:38055253]
8. Moore KN, Martin LP, O'Malley DM, Matulonis UA, Konner JA, Perez RP, Bauer TM, Ruiz-Soto R, Birrer MJ. (2017)
Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study.
J Clin Oncol, 35 (10): 1112-1118. [PMID:28029313]
9. Moore KN, Oza AM, Colombo N, Oaknin A, Scambia G, Lorusso D, Konecny GE, Banerjee S, Murphy CG, Tanyi JL et al.. (2021)
Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I.
Ann Oncol, 32 (6): 757-765. [PMID:33667670]
10. Scaranti M, Cojocaru E, Banerjee S, Banerji U. (2020)
Exploiting the folate receptor α in oncology.
Nat Rev Clin Oncol, 17 (6): 349-359. [PMID:32152484]